content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on February 3, 2025</B></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CADRENAL THERAPEUTICS, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)
  &nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 2%; text-align: center; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>88-0860746</B></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center">(State or other jurisdiction of<BR>
  </P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center">(I.R.S. Employer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center">Identification No.)</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>822 A1A North, Suite 306</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ponte Vedra, Florida 32082</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive Offices and Zip
  Code)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CADRENAL THERAPEUTICS,&nbsp;INC. 2022 SUCCSESOR
  EQUITY INCENTIVE PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CADRENAL THERAPEUTICS, INC. 2022 EQUITY INCENTIVE
  PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Full title of the plans)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Quang Pham<BR>
  Chief Executive Officer<BR>
  Cadrenal Therapeutics,&nbsp;Inc.<BR>
  822 A1A North, Suite 306</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ponte Vedra, Florida 32082<BR>
  (904) 300-0701</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, address, and telephone number, including
  area code, of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Please send copies of all communications
  to:</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Leslie Marlow,&nbsp;Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Blank Rome LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1271 Avenue of the Americas</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, New York 10020</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(212) 885-5000</B></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
      <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated Filer &#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller Reporting Company &#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company &#9746;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. &#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INTRODUCTION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cadrenal Therapeutics, Inc.
  (the &ldquo;Registrant&rdquo; or the &ldquo;Company&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
  its Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023004535/ea172057-s8_cadrenal.htm">Form S-8</A> (Registration No. 333-269372)
  on January 24, 2023 (the &ldquo;2023 Registration Statement&rdquo;), pursuant to and in accordance with the requirements of Form S-8 for
  the purpose of registering under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), 3,010,000 shares (pre-reverse
  stock split) (200,666 shares post-reverse stock split) of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common
  Stock&rdquo;), issuable to employees, officers, directors, consultants and advisors of the Company under the Registrant&rsquo;s 2022 Successor
  Equity Incentive Plan (the &ldquo;2022 Plan&rdquo;) and the Registrant&rsquo;s 2022 Equity Incentive Plan, as amended and restated (the
  &ldquo;Initial Plan&rdquo;). Pursuant to General Instruction E to Form S-8, the 2023 Registration Statement is incorporated into this
  Registration Statement by reference.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0.25in; text-align: justify">The
  Registrant also filed with the Commission its Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024021594/ea0201545-s8_cadrenal.htm">Form S-8</A> (Registration No. 333-277838) on March 12, 2024 (the
  &ldquo;March 2024 Registration Statement&rdquo;), pursuant to and in accordance with the requirements of General Instruction E to Form
  S-8, for the purpose of registering under the Securities Act an additional 694,550 shares (pre-reverse stock split) (46,303 shares post-reverse
  stock split) of Common Stock that may be issued pursuant to the 2022 Plan pursuant to an &ldquo;evergreen&rdquo; provision contained
  therein, which is equal to 20% of the total number of shares of Common Stock outstanding on December 31, 2023, resulting in a total of
  2,604,550 shares (pre-reverse stock split) (173,636 shares post-reverse stock split) of Common Stock available for issuance under the
  2022 Plan.&nbsp;Pursuant to General Instruction E to Form S-8, the March 2024 Registration Statement is incorporated into this Registration
  Statement by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 20, 2024, the
  Registrant effected a one-for-fifteen reverse stock split, which reduced the number of shares reserved under the 2022 Plan to 173,636.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Registrant also filed
  with the Commission its Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024111956/ea0225808-s8_cadrenal.htm">Form S-8</A> (Registration No. 333-284024) on December 23, 2024 (the &ldquo;December 2024
  Registration Statement&rdquo;), pursuant to and in accordance with the requirements of General Instruction E to Form S-8, for the purpose
  of registering under the Securities Act an additional 133,333 shares (post-reverse stock split) of the Common Stock that may be issued
  pursuant to the 2022 Plan, pursuant to an amendment to the 2022 Plan to increase the number of shares of Common Stock available for awards
  under the 2022 Plan by 133,333 (post-reverse stock split) shares of Common Stock to 306,969 (post-reverse stock split) shares of Common
  Stock, which amendment was approved by the Company&rsquo;s Board of Directors on May 25, 2024 and the Company&rsquo;s stockholders at
  its 2024 Annual Meeting of Stockholders held on July 29, 2024. Pursuant to General Instruction E to Form S-8, the December 2024 Registration
  Statement is incorporated into this Registration Statement by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to General Instruction
  E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 (the &ldquo;Registration Statement&rdquo;) for the purpose
  of registering under the Securities Act an additional 172,716 shares of Common Stock that may be issued pursuant to the Registrant&rsquo;s
  2022 Successor Equity Incentive Plan (the &ldquo;2022 Plan&rdquo;) pursuant to an &ldquo;evergreen&rdquo; provision contained therein,
  resulting in a total of 479,685 shares of Common Stock available for issuance under the 2022 Plan, which is equal to 20% of 2,398,426,
  the aggregate of: (i) the shares of Common Stock outstanding on December 31, 2024, and (ii) the shares of Common Stock issuable upon exercise
  of warrants and pre-funded&nbsp;warrants outstanding on December 31, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1. Plan Information*</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2. Registrant Information and Employee Plan Annual Information*</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">The information specified in Item 1 and Item 2 of Part I of
  this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities
  Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the introductory note to Part I of Form S-8. The documents containing
  the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428. Such documents and the
  documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken
  together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. Incorporation of Documents by Reference</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Securities and Exchange
  Commission (the &ldquo;Commission&rdquo;) allows us to &ldquo;incorporate by reference&rdquo; the information we file with it which means
  that we can disclose important information to you by referring you to those documents instead of having to repeat the information in this
  prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that we file
  with the Commission will automatically update and supersede this information. We incorporate by reference the documents listed below and
  any future filings made with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended
  (the &ldquo;Exchange Act&rdquo;), between the date of this prospectus and the termination of the offering:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Registrant&rsquo;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024021133/ea0201078-10k_cadrenal.htm">Form 10-K</A> for the year ended December 31, 2023 (Commission File No. 001-41596) filed with the Commission
  on March 11, 2024;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Registrant&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024041014/ea0205058-10q_cadrenal.htm">Form 10-Q</A> for the quarter ended March 31, 2024 (Commission File No. 001-41596) filed with the
  Commission on May 9, 2024;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Registrant&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024066107/ea0210248-10q_cadrenal.htm">Form 10-Q</A> for the quarter ended June 30, 2024 (Commission File No. 001-41596) filed with the Commission
  on August 7, 2024;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Registrant&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024095393/ea0218928-10q_cadrenal.htm">Form 10-Q</A> for the quarter ended September 30, 2024 (Commission File No. 001-41596) filed with
  the Commission on November 7, 2024;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Registrant&rsquo;s Current Reports on Form 8-K filed with the Commission on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024012649/ea193419-8k_cadrenal.htm">February 12, 2024</A></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024020181/ea0201254-8k_cadrenal.htm">March 5, 2024</A></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/ea0201524-8k_cadrenal.htm">March 12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024031371/ea0203558-8k_cadrenal.htm">April 9, 2024</A> (other than
  information furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024040955/ea020556601-8k_cadrenal.htm">May 9, 2024</A>, <FONT STYLE="background-color: white"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/ea0210326-8k_cadrenal.htm">July 31, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024065400/ea0210607-8k_cadrenal.htm">August 6, 2024</A> (other than information furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024069941/ea021156901-8k_cadrenal.htm">August 16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024070883/ea021179601-8k_cadrenal.htm">August 20, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024076144/ea021370601-8k_cadrenal.htm">September 5, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/ea0215596-8k_cadrenal.htm">September 25, 2024</A> </FONT>(other than information furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/ea0218502-8k_cadrenal.htm">October 24, 2024</A>
  (other than information furnished under Item 7.01 and exhibits related thereto) and <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024094155/ea0219768-8k_cadrenal.htm">November 4, 2024</A><FONT STYLE="background-color: white">;</FONT></FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024014316/ea193846-8ka1_cadrenal.htm">Form 8-K/A</A> filed with the SEC on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
  15, 2024</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  description of our common stock is set forth in our registration statement on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023003079/ea171784-8a12b_cadrenalthera.htm">Form 8-A</A></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;filed with the SEC on January 17, 2023,
  as updated by the description of our common stock filed as </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023024260/f10k2022ex4-11_cadrenal.htm">Exhibit 4.11</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to our Annual Report on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023024260/f10k2022_cadrenalth.htm">Form 10-K</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2022 filed with
  the SEC on March 30, 2023, including any amendments or reports filed for the purpose of updating such description.</FONT></TD>
  </TR></TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All other reports and documents
  subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than Current Reports furnished
  under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) shall be deemed to be incorporated
  by reference in this Registration Statement and to be a part of this Registration Statement from the respective date of filing of each
  of those reports or documents until the filing of a post-effective amendment to this Registration Statement which indicates either that
  all securities offered by this Registration Statement have been sold or which deregisters all of the securities under this Registration
  Statement then remaining unsold.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration
  Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration
  Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or
  superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"></P>
  
  <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt"></P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex3-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant&rsquo;s Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex3-2_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the registrant&rsquo;s Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024070883/ea021179601ex3-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant&rsquo;s Current Report on Form 8-K, filed on August 20, 2024, File No. 001-41596) </FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022941501ex5-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Blank Rome LLP</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022941501ex23-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of WithumSmith + Brown, PC, Independent Registered Public Accounting Firm</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022941501ex5-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Blank Rome LLP (contained in Exhibit 5.1)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page hereto)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics, Inc. 2022 Equity Incentive Plan and form of Incentive Stock Option Agreement, Non-Qualified Stock Option Agreement for Officers and Other Employees, Non-Qualified Stock Option Agreement for Directors and Consultants, Restricted Stock Agreement, and Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.1 to the registrant&rsquo;s Registration Statement on Form S-1, filed on September 22, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-14_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics, Inc. 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.14 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-15_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.15 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-16_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.16 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-17_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Grant Notice and Stock Option Agreement and Notice of Exercise under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.17 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-18_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.18 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.7</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024051803/ea0206592-04.htm#T9926"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference as Annex C to the Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A, filed on June 11, 2024, File No. 001-41596)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022941501ex-fee_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</FONT></A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
  herewith.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
  the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form&nbsp;S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
  authorized, in the City of Ponte Vedra, State of Florida, on this 3<SUP>rd</SUP> day of February, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CADRENAL THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
    <TR>
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 5%">&nbsp;</TD>
      <TD STYLE="width: 35%">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Quang Pham</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Each person whose signature
  appears below constitutes and appoints Quang Pham and Matthew Szot his true and lawful attorney-in-fact and agent with full power of substitution
  and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
  amendments) to this Registration Statement on Form&nbsp;S-8 to be filed by Cadrenal Therapeutics,&nbsp;Inc., and to file the same, with
  all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
  and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could
  do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause
  to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">***</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
  dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 33%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Signature</B></P></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 48%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Title</B></P></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 17%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Date</B></P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Quang Pham</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">Quang Pham</P></TD>
      <TD>&nbsp;</TD>
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">Chairman of the Board and Chief Executive Officer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">(Principal Executive Officer)</P></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 3, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Matthew Szot</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">Matthew Szot</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer<BR>
  (Principal Accounting and Financial Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 3, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ John R. Murphy</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">John R. Murphy</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 3, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Steven Zelenkofske</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">Steven Zelenkofske</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 3, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Glynn Wilson</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">Glynn Wilson</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0">&nbsp;</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 3, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Robert Lisicki</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 3, 2025</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Robert Lisicki</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 6; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 175pt"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0229415-s8_cadrenal.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 55922}]
metadata_filer: {"company-data": {"conformed-name": "Cadrenal Therapeutics, Inc.", "cik": "0001937993", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "880860746", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-284672", "film-number": "25583716"}, "business-address": {"street1": "822 A1A NORTH", "street2": "SUITE 306", "city": "PONTE VEDRA", "state": "FL", "zip": "32082", "phone": "904-300-0701"}, "mail-address": {"street1": "822 A1A NORTH", "street2": "SUITE 306", "city": "PONTE VEDRA", "state": "FL", "zip": "32082"}}
text: As filed with the Securities and Exchange Commission
  on February 3, 2025
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933
  CADRENAL THERAPEUTICS, INC.
  (Exact name of registrant as specified in its charter)
  Delaware
  88-0860746
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  822 A1A North, Suite 306
  Ponte Vedra, Florida 32082
  (Address of Principal Executive Offices and Zip
  Code)
  CADRENAL THERAPEUTICS, INC. 2022 SUCCSESOR
  EQUITY INCENTIVE PLAN
  CADRENAL THERAPEUTICS, INC. 2022 EQUITY INCENTIVE
  PLAN
  (Full title of the plans)
  Quang Pham
  Chief Executive Officer
  Cadrenal Therapeutics, Inc.
  822 A1A North, Suite 306
  Ponte Vedra, Florida 32082
  (904) 300-0701
  (Name, address, and telephone number, including
  area code, of agent for service)
  Please send copies of all communications
  to:
  Leslie Marlow, Esq.
  Blank Rome LLP
  1271 Avenue of the Americas
  New York, New York 10020
  (212) 885-5000
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer ☐
  Accelerated Filer ☐
  Non-accelerated filer ☒
  Smaller Reporting Company ☒
  Emerging Growth Company ☒
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  INTRODUCTION
  Cadrenal Therapeutics, Inc.
  (the "Registrant" or the "Company") filed with the Securities and Exchange Commission (the "Commission")
  its Registration Statement on
  Form S-8
  (Registration No. 333-269372)
  on January 24, 2023 (the "2023 Registration Statement"), pursuant to and in accordance with the requirements of Form S-8 for
  the purpose of registering under the Securities Act of 1933, as amended (the "Securities Act"), 3,010,000 shares (pre-reverse
  stock split) (200,666 shares post-reverse stock split) of the Company's common stock, par value $0.001 per share (the "Common
  Stock"), issuable to employees, officers, directors, consultants and advisors of the Company under the Registrant's 2022 Successor
  Equity Incentive Plan (the "2022 Plan") and the Registrant's 2022 Equity Incentive Plan, as amended and restated (the
  "Initial Plan"). Pursuant to General Instruction E to Form S-8, the 2023 Registration Statement is incorporated into this
  Registration Statement by reference.
  The
  Registrant also filed with the Commission its Registration Statement on
  Form S-8
  (Registration No. 333-277838) on March 12, 2024 (the
  "March 2024 Registration Statement"), pursuant to and in accordance with the requirements of General Instruction E to Form
  S-8, for the purpose of registering under the Securities Act an additional 694,550 shares (pre-reverse stock split) (46,303 shares post-reverse
  stock split) of Common Stock that may be issued pursuant to the 2022 Plan pursuant to an "evergreen" provision contained
  therein, which is equal to 20% of the total number of shares of Common Stock outstanding on December 31, 2023, resulting in a total of
  2,604,550 shares (pre-reverse stock split) (173,636 shares post-reverse stock split) of Common Stock available for issuance under the
  2022 Plan. Pursuant to General Instruction E to Form S-8, the March 2024 Registration Statement is incorporated into this Registration
  Statement by reference.
  On August 20, 2024, the
  Registrant effected a one-for-fifteen reverse stock split, which reduced the number of shares reserved under the 2022 Plan to 173,636.
  The Registrant also filed
  with the Commission its Registration Statement on
  Form S-8
  (Registration No. 333-284024) on December 23, 2024 (the "December 2024
  Registration Statement"), pursuant to and in accordance with the requirements of General Instruction E to Form S-8, for the purpose
  of registering under the Securities Act an additional 133,333 shares (post-reverse stock split) of the Common Stock that may be issued
  pursuant to the 2022 Plan, pursuant to an amendment to the 2022 Plan to increase the number of shares of Common Stock available for awards
  under the 2022 Plan by 133,333 (post-reverse stock split) shares of Common Stock to 306,969 (post-reverse stock split) shares of Common
  Stock, which amendment was approved by the Company's Board of Directors on May 25, 2024 and the Company's stockholders at
  its 2024 Annual Meeting of Stockholders held on July 29, 2024. Pursuant to General Instruction E to Form S-8, the December 2024 Registration
  Statement is incorporated into this Registration Statement by reference.
  Pursuant to General Instruction
  E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 (the "Registration Statement") for the purpose
  of registering under the Securities Act an additional 172,716 shares of Common Stock that may be issued pursuant to the Registrant's
  2022 Successor Equity Incentive Plan (the "2022 Plan") pursuant to an "evergreen" provision contained therein,
  resulting in a total of 479,685 shares of Common Stock available for issuance under the 2022 Plan, which is equal to 20% of 2,398,426,
  the aggregate of: (i) the shares of Common Stock outstanding on December 31, 2024, and (ii) the shares of Common Stock issuable upon exercise
  of warrants and pre-funded warrants outstanding on December 31, 2024.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  Item 1. Plan Information*
  Item 2. Registrant Information and Employee Plan Annual Information*
  *
  The information specified in Item 1 and Item 2 of Part I of
  this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities
  Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of Form S-8. The documents containing
  the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428. Such documents and the
  documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken
  together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference
  The Securities and Exchange
  Commission (the "Commission") allows us to "incorporate by reference" the information we file with it which means
  that we can disclose important information to you by referring you to those documents instead of having to repeat the information in this
  prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that we file
  with the Commission will automatically update and supersede this information. We incorporate by reference the documents listed below and
  any future filings made with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended
  (the "Exchange Act"), between the date of this prospectus and the termination of the offering:
  ●
  The
  Registrant's Annual Report on
  Form 10-K
  for the year ended December 31, 2023 (Commission File No. 001-41596) filed with the Commission
  on March 11, 2024;
  ●
  The
  Registrant's Quarterly Report on
  Form 10-Q
  for the quarter ended March 31, 2024 (Commission File No. 001-41596) filed with the
  Commission on May 9, 2024;
  ●
  The
  Registrant's Quarterly Report on
  Form 10-Q
  for the quarter ended June 30, 2024 (Commission File No. 001-41596) filed with the Commission
  on August 7, 2024;
  ●
  The
  Registrant's Quarterly Report on
  Form 10-Q
  for the quarter ended September 30, 2024 (Commission File No. 001-41596) filed with
  the Commission on November 7, 2024;
  ●
  The
  Registrant's Current Reports on Form 8-K filed with the Commission on
  February 12, 2024
  ,
  March 5, 2024
  ,
  March 12, 2024
  ,
  April 9, 2024
  (other than
  information furnished under Item 7.01 and exhibits related thereto),
  May 9, 2024
  ,
  July 31, 2024
  ,
  August 6, 2024
  (other than information furnished under Item 7.01 and exhibits related thereto),
  August 16, 2024
  ,
  August 20, 2024
  ,
  September 5, 2024
  ,
  September 25, 2024
  (other than information furnished under Item 7.01 and exhibits related thereto),
  October 24, 2024
  (other than information furnished under Item 7.01 and exhibits related thereto) and
  November 4, 2024
  ;
  ●
  Our
  Current Report on
  Form 8-K/A
  filed with the SEC on
  February
  15, 2024
  ; and
  ●
  The
  description of our common stock is set forth in our registration statement on
  Form 8-A
  filed with the SEC on January 17, 2023,
  as updated by the description of our common stock filed as
  Exhibit 4.11
  to our Annual Report on
  Form 10-K
  for the year ended December 31, 2022 filed with
  the SEC on March 30, 2023, including any amendments or reports filed for the purpose of updating such description.
  All other reports and documents
  subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than Current Reports furnished
  under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) shall be deemed to be incorporated
  by reference in this Registration Statement and to be a part of this Registration Statement from the respective date of filing of each
  of those reports or documents until the filing of a post-effective amendment to this Registration Statement which indicates either that
  all securities offered by this Registration Statement have been sold or which deregisters all of the securities under this Registration
  Statement then remaining unsold.
  Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration
  Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration
  Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or
  superseded, to constitute a part of this Registration Statement.
  II-
  1
  PART II
  INFORMATION REQUIRED IN REGISTRATION STATEMENT
  Item 8. Exhibits.
  Exhibit
  Description
  4.1
  Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant's Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)
  4.2
  Amended and Restated Bylaws of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the registrant's Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)
  4.3
  Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K, filed on August 20, 2024, File No. 001-41596)
  5.1*
  Opinion of Blank Rome LLP
  23.1*
  Consent of WithumSmith + Brown, PC, Independent Registered Public Accounting Firm
  23.2*
  Consent of Blank Rome LLP (contained in Exhibit 5.1)
  24.1*
  Power of Attorney (included on signature page hereto)
  99.1
  Cadrenal Therapeutics, Inc. 2022 Equity Incentive Plan and form of Incentive Stock Option Agreement, Non-Qualified Stock Option Agreement for Officers and Other Employees, Non-Qualified Stock Option Agreement for Directors and Consultants, Restricted Stock Agreement, and Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.1 to the registrant's Registration Statement on Form S-1, filed on September 22, 2022, File No. 333-267562)
  99.2
  Cadrenal Therapeutics, Inc. 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.14 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.3
  Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.15 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.4
  Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.16 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.5
  Form of Stock Option Grant Notice and Stock Option Agreement and Notice of Exercise under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.17 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.6
  Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.18 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.7
  Amendment to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference as Annex C to the Registrant's Definitive Proxy Statement on Schedule 14A, filed on June 11, 2024, File No. 001-41596)
  107*
  Filing Fee Table
  *
  Filed
  herewith.
  II-
  2
  SIGNATURES
  Pursuant to the requirements of
  the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
  filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
  authorized, in the City of Ponte Vedra, State of Florida, on this 3
  rd
  day of February, 2025.
  CADRENAL THERAPEUTICS, INC.
  By:
  /s/ Quang Pham
  Name:
  Quang Pham
  Title:
  Chairman of the Board and Chief Executive Officer
  POWER OF ATTORNEY
  Each person whose signature
  appears below constitutes and appoints Quang Pham and Matthew Szot his true and lawful attorney-in-fact and agent with full power of substitution
  and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
  amendments) to this Registration Statement on Form S-8 to be filed by Cadrenal Therapeutics, Inc., and to file the same, with
  all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
  and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could
  do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause
  to be done by virtue hereof.
  ***
  Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
  dates indicated.
  Signature
  Title
  Date
  /s/ Quang Pham
  Quang Pham
  Chairman of the Board and Chief Executive Officer
  (Principal Executive Officer)
  February 3, 2025
  /s/ Matthew Szot
  Matthew Szot
  Chief Financial Officer
  (Principal Accounting and Financial Officer)
  February 3, 2025
  /s/ John R. Murphy
  John R. Murphy
  Director
  February 3, 2025
  /s/ Steven Zelenkofske
  Steven Zelenkofske
  Director
  February 3, 2025
  /s/ Glynn Wilson
  Glynn Wilson
  Director
  February 3, 2025
  /s/ Robert Lisicki
  Director
  February 3, 2025
  Robert Lisicki
  II-
  3